Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 1683 entries
Sorted by: Best Match Show Resources per page
Clinical management of gender dysphoria in children and adolescents: the Dutch approach

gender (e.g., male, women, girls, transgender)

De ALC, Cohen-Kettenis PT.
GSID: SJPpiMoZyHEJ
ALC De Vries, PT Cohen-Kettenis - Journal of homosexuality, 2012 - Taylor & Francis

… may be unrelated to the gender presentation but still need attention (eg, tic disorders). There … puberty of the desired gender. Male-to-females (MTF) or trans girls receive estrogens which …

Cite
De Vries, A. L., & Cohen-Kettenis, P. T. (2012). Clinical management of gender dysphoria in children and adolescents: the Dutch approach. Journal of homosexuality, 59(3), 301-320.
De Vries, Annelou LC, and Peggy T. Cohen-Kettenis. "Clinical management of gender dysphoria in children and adolescents: the Dutch approach." Journal of homosexuality 59.3 (2012): 301-320.
Copy Download .nbib Format: MLA
GPER Signaling in Spermatogenesis and Testicular Tumors.

Frontiers in endocrinology

Chimento A, Sirianni R, Casaburi I, Pezzi V.
PMID: 24639669
Front Endocrinol (Lausanne). 2014 Mar 06;5:30. doi: 10.3389/fendo.2014.00030. eCollection 2014.

Estrogens play important roles in the regulation of testis development and spermatogenesis. Moreover, several evidences suggest that estrogen signaling can be involved in testicular tumorigenesis. The physiological effects of estrogen are mediated by the classical nuclear estrogen receptors ESR1...

Cite
Chimento A, Sirianni R, Casaburi I, et al. GPER Signaling in Spermatogenesis and Testicular Tumors. Front Endocrinol (Lausanne). 2014;5:30doi: 10.3389/fendo.2014.00030.
Chimento, A., Sirianni, R., Casaburi, I., & Pezzi, V. (2014). GPER Signaling in Spermatogenesis and Testicular Tumors. Frontiers in endocrinology, 530. https://doi.org/10.3389/fendo.2014.00030
Chimento, Adele, et al. "GPER Signaling in Spermatogenesis and Testicular Tumors." Frontiers in endocrinology vol. 5 (2014): 30. doi: https://doi.org/10.3389/fendo.2014.00030
Chimento A, Sirianni R, Casaburi I, Pezzi V. GPER Signaling in Spermatogenesis and Testicular Tumors. Front Endocrinol (Lausanne). 2014 Mar 06;5:30. doi: 10.3389/fendo.2014.00030. eCollection 2014. PMID: 24639669; PMCID: PMC3944538.
Copy Download .nbib Format: NLM
Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study.

Advances and applications in bioinformatics and chemistry : AABC

Hasan TN, B LG, Masoodi TA, Shafi G, Alshatwi AA, Sivashanmugham P.
PMID: 21918635
Adv Appl Bioinform Chem. 2011;4:29-36. doi: 10.2147/AABC.S17371. Epub 2011 Mar 08.

BACKGROUND: The human progesterone receptor (hPR) belongs to the steroid receptor family. It may be found as monomers (A and B) and or as a dimer (AB). hPR is regarded as the prognostic biomarker for breast cancer. In a...

Cite
Hasan TN, B LG, Masoodi TA, et al. Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Adv Appl Bioinform Chem. 2011;4:29-36doi: 10.2147/AABC.S17371.
Hasan, T. N., B, L. G., Masoodi, T. A., Shafi, G., Alshatwi, A. A., & Sivashanmugham, P. (2011). Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Advances and applications in bioinformatics and chemistry : AABC, 429-36. https://doi.org/10.2147/AABC.S17371
Hasan, Tarique N, et al. "Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study." Advances and applications in bioinformatics and chemistry : AABC vol. 4 (2011): 29-36. doi: https://doi.org/10.2147/AABC.S17371
Hasan TN, B LG, Masoodi TA, Shafi G, Alshatwi AA, Sivashanmugham P. Affinity of estrogens for human progesterone receptor A and B monomers and risk of breast cancer: a comparative molecular modeling study. Adv Appl Bioinform Chem. 2011;4:29-36. doi: 10.2147/AABC.S17371. Epub 2011 Mar 08. PMID: 21918635; PMCID: PMC3169952.
Copy Download .nbib Format: NLM
Comparison of Vaginal versus Oral Estradiol Administration in Improving the Visualization of Transformation Zone (TZ) during Colposcopy.

Journal of clinical and diagnostic research : JCDR

Beniwal S, Makkar B, Batra S, Gandhi G, Goswami D, Zutshi V.
PMID: 27630912
J Clin Diagn Res. 2016 Jul;10(7):QC18-21. doi: 10.7860/JCDR/2016/19492.8201. Epub 2016 Jul 01.

INTRODUCTION: Colposcopy is an important diagnostic tool in the evaluation of patients with abnormal pap smears. However, in 10-20% transformation zone (TZ)/squamo-columnar junction is not completely visualized and these patients are deemed to have an incomplete colposcopy examination. Such...

Cite
Beniwal S, Makkar B, Batra S, et al. Comparison of Vaginal versus Oral Estradiol Administration in Improving the Visualization of Transformation Zone (TZ) during Colposcopy. J Clin Diagn Res. 2016;10(7):QC18-21doi: 10.7860/JCDR/2016/19492.8201.
Beniwal, S., Makkar, B., Batra, S., Gandhi, G., Goswami, D., & Zutshi, V. (2016). Comparison of Vaginal versus Oral Estradiol Administration in Improving the Visualization of Transformation Zone (TZ) during Colposcopy. Journal of clinical and diagnostic research : JCDR, 10(7), QC18-21. https://doi.org/10.7860/JCDR/2016/19492.8201
Beniwal, Seema, et al. "Comparison of Vaginal versus Oral Estradiol Administration in Improving the Visualization of Transformation Zone (TZ) during Colposcopy." Journal of clinical and diagnostic research : JCDR vol. 10,7 (2016): QC18-21. doi: https://doi.org/10.7860/JCDR/2016/19492.8201
Beniwal S, Makkar B, Batra S, Gandhi G, Goswami D, Zutshi V. Comparison of Vaginal versus Oral Estradiol Administration in Improving the Visualization of Transformation Zone (TZ) during Colposcopy. J Clin Diagn Res. 2016 Jul;10(7):QC18-21. doi: 10.7860/JCDR/2016/19492.8201. Epub 2016 Jul 01. PMID: 27630912; PMCID: PMC5020212.
Copy Download .nbib Format: NLM
Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression.

Bladder cancer (Amsterdam, Netherlands)

Godoy G, Gakis G, Smith CL, Fahmy O.
PMID: 27376135
Bladder Cancer. 2016 Apr 27;2(2):127-137. doi: 10.3233/BLC-160052.

Epidemiologic studies have long demonstrated clear differences in incidence and progression of bladder cancer between genders suggesting that the mechanisms of development and progression in these tumors have a strong association with steroid hormonal pathways. Such observations led to...

Cite
Godoy G, Gakis G, Smith CL, et al. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer. 2016;2(2):127-137doi: 10.3233/BLC-160052.
Godoy, G., Gakis, G., Smith, C. L., & Fahmy, O. (2016). Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder cancer (Amsterdam, Netherlands), 2(2), 127-137. https://doi.org/10.3233/BLC-160052
Godoy, Guilherme, et al. "Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression." Bladder cancer (Amsterdam, Netherlands) vol. 2,2 (2016): 127-137. doi: https://doi.org/10.3233/BLC-160052
Godoy G, Gakis G, Smith CL, Fahmy O. Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression. Bladder Cancer. 2016 Apr 27;2(2):127-137. doi: 10.3233/BLC-160052. PMID: 27376135; PMCID: PMC4927898.
Copy Download .nbib Format: NLM
Estradiol: micrograms or milligrams.

Endocrinology, diabetes & metabolism case reports

Kirk JM, Wickramasuriya N, Shaw NJ.
PMID: 26843960
Endocrinol Diabetes Metab Case Rep. 2016;2016:150096. doi: 10.1530/EDM-15-0096. Epub 2016 Jan 06.

UNLABELLED: Estrogen is used to induce puberty in peripubertal girls with hypogonadism. Although both synthetic and natural forms are available, along with different routes of administration, in the UK oral ethinyl estradiol and the low-dose oral contraceptive pill are...

Cite
Kirk JM, Wickramasuriya N, Shaw NJ. Estradiol: micrograms or milligrams. Endocrinol Diabetes Metab Case Rep. 2016;2016:150096doi: 10.1530/EDM-15-0096.
Kirk, J. M., Wickramasuriya, N., & Shaw, N. J. (2016). Estradiol: micrograms or milligrams. Endocrinology, diabetes & metabolism case reports, 2016150096. https://doi.org/10.1530/EDM-15-0096
Kirk, Jeremy M W, et al. "Estradiol: micrograms or milligrams." Endocrinology, diabetes & metabolism case reports vol. 2016 (2016): 150096. doi: https://doi.org/10.1530/EDM-15-0096
Kirk JM, Wickramasuriya N, Shaw NJ. Estradiol: micrograms or milligrams. Endocrinol Diabetes Metab Case Rep. 2016;2016:150096. doi: 10.1530/EDM-15-0096. Epub 2016 Jan 06. PMID: 26843960; PMCID: PMC4738193.
Copy Download .nbib Format: NLM
A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age.

Obstetrics and gynecology international

Roehm E.
PMID: 25685151
Obstet Gynecol Int. 2015;2015:713295. doi: 10.1155/2015/713295. Epub 2015 Jan 01.

The Women's Health Initiative (WHI) Estrogen-Alone Trial randomized postmenopausal women, 50 to 79 years of age, with prior hysterectomy, to conjugated equine estrogens (CEE) or placebo with a 5.9-year median duration of CEE use. In 2013, the WHI published...

Cite
Roehm E. A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age. Obstet Gynecol Int. 2015;2015:713295doi: 10.1155/2015/713295.
Roehm, E. (2015). A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age. Obstetrics and gynecology international, 2015713295. https://doi.org/10.1155/2015/713295
Roehm, Eric. "A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age." Obstetrics and gynecology international vol. 2015 (2015): 713295. doi: https://doi.org/10.1155/2015/713295
Roehm E. A Reappraisal of Women's Health Initiative Estrogen-Alone Trial: Long-Term Outcomes in Women 50-59 Years of Age. Obstet Gynecol Int. 2015;2015:713295. doi: 10.1155/2015/713295. Epub 2015 Jan 01. PMID: 25685151; PMCID: PMC4313058.
Copy Download .nbib Format: NLM
The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases.

Frontiers in immunology

Khan D, Ansar Ahmed S.
PMID: 26779182
Front Immunol. 2016 Jan 06;6:635. doi: 10.3389/fimmu.2015.00635. eCollection 2015.

Analogous to other physiological systems, the immune system also demonstrates remarkable sex differences. Although the reasons for sex differences in immune responses are not precisely understood, it potentially involves differences in sex hormones (estrogens, androgens, and differential sex hormone...

Cite
Khan D, Ansar Ahmed S. The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases. Front Immunol. 2016;6:635doi: 10.3389/fimmu.2015.00635.
Khan, D., & Ansar Ahmed, S. (2015). The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases. Frontiers in immunology, 6635. https://doi.org/10.3389/fimmu.2015.00635
Khan, Deena, and Ansar Ahmed, S. "The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases." Frontiers in immunology vol. 6 (2015): 635. doi: https://doi.org/10.3389/fimmu.2015.00635
Khan D, Ansar Ahmed S. The Immune System Is a Natural Target for Estrogen Action: Opposing Effects of Estrogen in Two Prototypical Autoimmune Diseases. Front Immunol. 2016 Jan 06;6:635. doi: 10.3389/fimmu.2015.00635. eCollection 2015. PMID: 26779182; PMCID: PMC4701921.
Copy Download .nbib Format: NLM
Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility.

Frontiers in endocrinology

Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti RM, Limonta P.
PMID: 27833586
Front Endocrinol (Lausanne). 2016 Oct 26;7:140. doi: 10.3389/fendo.2016.00140. eCollection 2016.

Cutaneous melanoma is an aggressive tumor; its incidence has been reported to increase fast in the past decades. Melanoma is a heterogeneous tumor, with most patients harboring mutations in the BRAF or NRAS oncogenes, leading to the overactivation of...

Cite
Marzagalli M, Montagnani Marelli M, Casati L, et al. Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne). 2016;7:140doi: 10.3389/fendo.2016.00140.
Marzagalli, M., Montagnani Marelli, M., Casati, L., Fontana, F., Moretti, R. M., & Limonta, P. (2016). Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Frontiers in endocrinology, 7140. https://doi.org/10.3389/fendo.2016.00140
Marzagalli, Monica, et al. "Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility." Frontiers in endocrinology vol. 7 (2016): 140. doi: https://doi.org/10.3389/fendo.2016.00140
Marzagalli M, Montagnani Marelli M, Casati L, Fontana F, Moretti RM, Limonta P. Estrogen Receptor β in Melanoma: From Molecular Insights to Potential Clinical Utility. Front Endocrinol (Lausanne). 2016 Oct 26;7:140. doi: 10.3389/fendo.2016.00140. eCollection 2016. PMID: 27833586; PMCID: PMC5080294.
Copy Download .nbib Format: NLM
Estrogens - the Saviors of Cognitive Function?.

Breast care (Basel, Switzerland)

Pfeiler G.
PMID: 27721709
Breast Care (Basel). 2016 Aug;11(4):238-239. doi: 10.1159/000448636. Epub 2016 Aug 09.

No abstract available.

Cite
Pfeiler G. Estrogens - the Saviors of Cognitive Function?. Breast Care (Basel). 2016;11(4):238-239doi: 10.1159/000448636.
Pfeiler, G. (2016). Estrogens - the Saviors of Cognitive Function?. Breast care (Basel, Switzerland), 11(4), 238-239. https://doi.org/10.1159/000448636
Pfeiler, Georg. "Estrogens - the Saviors of Cognitive Function?." Breast care (Basel, Switzerland) vol. 11,4 (2016): 238-239. doi: https://doi.org/10.1159/000448636
Pfeiler G. Estrogens - the Saviors of Cognitive Function?. Breast Care (Basel). 2016 Aug;11(4):238-239. doi: 10.1159/000448636. Epub 2016 Aug 09. PMID: 27721709; PMCID: PMC5040898.
Copy Download .nbib Format: NLM
Estradiol Uses Different Mechanisms in Astrocytes from the Hippocampus of Male and Female Rats to Protect against Damage Induced by Palmitic Acid.

Frontiers in molecular neuroscience

Frago LM, Canelles S, Freire-Regatillo A, Argente-Arizón P, Barrios V, Argente J, Garcia-Segura LM, Chowen JA.
PMID: 29114202
Front Mol Neurosci. 2017 Oct 24;10:330. doi: 10.3389/fnmol.2017.00330. eCollection 2017.

An excess of saturated fatty acids can be toxic for tissues, including the brain, and this has been associated with the progression of neurodegenerative diseases. Since palmitic acid (PA) is a free fatty acid that is abundant in the...

Cite
Frago LM, Canelles S, Freire-Regatillo A, et al. Estradiol Uses Different Mechanisms in Astrocytes from the Hippocampus of Male and Female Rats to Protect against Damage Induced by Palmitic Acid. Front Mol Neurosci. 2017;10:330doi: 10.3389/fnmol.2017.00330.
Frago, L. M., Canelles, S., Freire-Regatillo, A., Argente-Arizón, P., Barrios, V., Argente, J., Garcia-Segura, L. M., & Chowen, J. A. (2017). Estradiol Uses Different Mechanisms in Astrocytes from the Hippocampus of Male and Female Rats to Protect against Damage Induced by Palmitic Acid. Frontiers in molecular neuroscience, 10330. https://doi.org/10.3389/fnmol.2017.00330
Frago, Laura M, et al. "Estradiol Uses Different Mechanisms in Astrocytes from the Hippocampus of Male and Female Rats to Protect against Damage Induced by Palmitic Acid." Frontiers in molecular neuroscience vol. 10 (2017): 330. doi: https://doi.org/10.3389/fnmol.2017.00330
Frago LM, Canelles S, Freire-Regatillo A, Argente-Arizón P, Barrios V, Argente J, Garcia-Segura LM, Chowen JA. Estradiol Uses Different Mechanisms in Astrocytes from the Hippocampus of Male and Female Rats to Protect against Damage Induced by Palmitic Acid. Front Mol Neurosci. 2017 Oct 24;10:330. doi: 10.3389/fnmol.2017.00330. eCollection 2017. PMID: 29114202; PMCID: PMC5660686.
Copy Download .nbib Format: NLM
Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention.

Frontiers in pharmacology

Nocera NF, Lee MC, De La Cruz LM, Rosemblit C, Czerniecki BJ.
PMID: 27766079
Front Pharmacol. 2016 Oct 06;7:356. doi: 10.3389/fphar.2016.00356. eCollection 2016.

The ErbB/B2 (HER-2/neu) oncogene family plays a critical role in the development and metastatic spread of several tumor types including breast, ovarian and gastric cancer. In breast cancer, HER-2/neu is expressed in early disease development in a large percentage...

Cite
Nocera NF, Lee MC, De La Cruz LM, et al. Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Front Pharmacol. 2016;7:356doi: 10.3389/fphar.2016.00356.
Nocera, N. F., Lee, M. C., De La Cruz, L. M., Rosemblit, C., & Czerniecki, B. J. (2016). Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Frontiers in pharmacology, 7356. https://doi.org/10.3389/fphar.2016.00356
Nocera, Nadia F, et al. "Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention." Frontiers in pharmacology vol. 7 (2016): 356. doi: https://doi.org/10.3389/fphar.2016.00356
Nocera NF, Lee MC, De La Cruz LM, Rosemblit C, Czerniecki BJ. Restoring Lost Anti-HER-2 Th1 Immunity in Breast Cancer: A Crucial Role for Th1 Cytokines in Therapy and Prevention. Front Pharmacol. 2016 Oct 06;7:356. doi: 10.3389/fphar.2016.00356. eCollection 2016. PMID: 27766079; PMCID: PMC5052279.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 1683 entries